CN112773802A - 一种化合物用于预防或治疗移植物抗宿主病的用途 - Google Patents
一种化合物用于预防或治疗移植物抗宿主病的用途 Download PDFInfo
- Publication number
- CN112773802A CN112773802A CN202011235745.8A CN202011235745A CN112773802A CN 112773802 A CN112773802 A CN 112773802A CN 202011235745 A CN202011235745 A CN 202011235745A CN 112773802 A CN112773802 A CN 112773802A
- Authority
- CN
- China
- Prior art keywords
- host disease
- gvhd
- versus host
- graft versus
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000009329 Graft vs Host Disease Diseases 0.000 title claims abstract description 84
- 208000024908 graft versus host disease Diseases 0.000 title claims abstract description 84
- 150000001875 compounds Chemical class 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 32
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 33
- 229910052717 sulfur Inorganic materials 0.000 claims description 24
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 18
- 239000001301 oxygen Substances 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 15
- 208000024340 acute graft versus host disease Diseases 0.000 claims description 13
- 230000004083 survival effect Effects 0.000 claims description 13
- 208000017760 chronic graft versus host disease Diseases 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000011593 sulfur Substances 0.000 claims description 9
- 239000003862 glucocorticoid Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 8
- 229960002930 sirolimus Drugs 0.000 claims description 8
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 8
- 230000004584 weight gain Effects 0.000 claims description 8
- 235000019786 weight gain Nutrition 0.000 claims description 8
- -1 C1-6Alkylene radical Chemical class 0.000 claims description 7
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 6
- 229960004584 methylprednisolone Drugs 0.000 claims description 6
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 6
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 6
- 150000003254 radicals Chemical class 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 5
- 108010036949 Cyclosporine Proteins 0.000 claims description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 5
- 229960001265 ciclosporin Drugs 0.000 claims description 5
- 229930182912 cyclosporin Natural products 0.000 claims description 5
- 229960000485 methotrexate Drugs 0.000 claims description 5
- 229960002340 pentostatin Drugs 0.000 claims description 5
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 5
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 229940046731 calcineurin inhibitors Drugs 0.000 claims description 4
- 229910052736 halogen Chemical group 0.000 claims description 4
- 150000002367 halogens Chemical group 0.000 claims description 4
- 229960004618 prednisone Drugs 0.000 claims description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 4
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 4
- 229960003433 thalidomide Drugs 0.000 claims description 4
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 230000000735 allogeneic effect Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 208000021017 Weight Gain Diseases 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 238000010322 bone marrow transplantation Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 125000001897 prednisolone group Chemical group 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000011519 second-line treatment Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029888 Obliterative bronchiolitis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- PQGAHNJECSVDEI-UHFFFAOYSA-N [CH2]CCCCC Chemical compound [CH2]CCCCC PQGAHNJECSVDEI-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 201000003848 bronchiolitis obliterans Diseases 0.000 description 1
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004296 naive t lymphocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Description
技术领域
本发明涉及一种化合物在制备用于预防或治疗移植物抗宿主病(GVHD)的药物中的用途。
背景技术
移植物抗宿主病(GVHD)是同种异体造血干细胞移植(HSCT)后最常见的并发症。尽管有强力的免疫抑制预防,甚至当供体是完全匹配的(HLA相同的)兄弟姐妹时,也可以发生GVHD。这是受体的抗原呈递细胞和供体的成熟细胞之间相互作用的结果。移植物中的免疫细胞也会对宿主组织造成免疫损害,并引起非疾病复发性的死亡。GVHD在接受移植并长期生存的患者中的发生率在20-80%之间,是临床移植手术需要关注的常见问题。根据中华医学会血液学分会的数据,中国每年接受异基因骨髓移植的患者超过5000例,所有患者都需要接受GVHD的预防和治疗。
GVHD按照发生时间通常分为急性GVHD(aGVHD)和慢性GVHD(cGVHD)。aGVHD通常发生在移植后3个月内,最迟6个月内发生,aGVHD主要涉及的三种器官是皮肤、胃肠道和肝;而在移植6个月以后的任何时间段都有可能发生cGVHD,cGVHD攻击的屏障组织包括眼、口、肠或生殖器粘膜区以及闭塞性细支气管炎中涉及粘膜的上皮屏障。接受移植的患者采用免疫抑制治疗的中位时间通常需要2-3年。
aGVHD的一线治疗采用肾上腺皮质激素甲基强的松龙静脉注射,激素治疗无效的患者采用二线治疗包括他克莫司或麦考酚酸酯或与甲基强的松龙联用。小分子靶向药物JAK抑制剂Ruxolitinib最近获批用于急性期的二线治疗但是在国内还没有上市。GVHD出现越早,预后越差,因此临床需要积极处理。
cGVHD治疗的标准一线方案为早期开始给予强的松龙和硫唑嘌呤联用,并逐渐减量,如患者不耐受,也可采用强的松龙联合环孢素。二线治疗则可以选用他克莫司或利托昔单抗或伊马替尼或喷司他汀等,二线药物单药无效时优先考虑二线药物之间的联合。进入三线治疗选择的药物更少,可以采用冲击剂量的激素治疗或麦考酚酸酯或甲氨喋呤等。
T淋巴细胞活化是诱导GVHD发生、发展的首要环节,移植前接受放化疗及移植后的GVHD均会造成TEC的损伤导致标准的中心耐受机制受限,无法去除反应性T、B淋巴细胞,尤其幼稚T淋巴细胞(未经历抗原)诱导更严重的GVHD。aGVHD的发生可能涉及JAK/STAT及NK-κB通路对GVHD的炎症介质和T淋巴细胞亚群的调节。
仍需要用于预防或治疗移植物抗宿主病(GVHD)的药物,尤其是用于改善移植物抗宿主病(GVHD)患者的存活率或体重的增长的药物。
发明内容
本发明的目的是提供用于预防或治疗移植物抗宿主病(GVHD)的药物。本发明的另一个目的是提供用于改善移植物抗宿主病(GVHD)患者的存活率或体重的增长的药物。
在一个方面,本发明涉及式(I)的化合物或其药学上可接受的盐在制备用于预防或治疗移植物抗宿主病(GVHD)的药物中的用途,
其中,
R1为卤素,
R2为卤素,
R3选自C1-6烷基、C2-6烯基或C2-6炔基,
R4选自-CN或卤素,
X1选自O、S、NH或CH2,
X2选自O、S、NH或CH2,
Q1选自NH、CH2、O或S,
Q2选自NH、CH2、O或S,
Q3选自NH、CH2、O或S,
Q4选自N-R5或CH-R5,其中R5选自C1-6烷基、C2-6烯基或C2-6炔基,且
L1选自C1-6亚烷基、C2-6亚烯基或C2-6亚炔基。
在一个方面,式(I)中,R3为C2-6烯基,R4为-CN,X1为O,X2为O,Q1为NH,Q2为NH,Q3为NH,Q4为N-R5,R5为C1-6烷基,且L1为C1-6亚烷基。
在一个方面,所述式(I)的化合物为化合物CS12192:
在一个方面,所述移植物抗宿主病为急性移植物抗宿主病(aGVHD)或慢性移植物抗宿主病(cGVHD)。
在一个方面,所述药物用于改善移植物抗宿主病(GVHD)患者的存活率。
在一个方面,所述药物用于改善移植物抗宿主病(GVHD)患者的体重的增长。
在一个方面,所述药物还包括用于预防或治疗移植物抗宿主病(GVHD)的其它活性成分。优选地,所述其它活性成分选自糖皮质激素、钙调神经磷酸酶抑制剂、霉酚酸酯、西罗莫司、喷司他丁、抗CD25单克隆抗体、抗TNFa单克隆抗体、环孢素、甲氨喋呤、沙利度胺或雷帕霉素。优选地,所述糖皮质激素选自泼尼松或甲基泼尼松龙。
在一个方面,本发明涉及用于预防或治疗移植物抗宿主病(GVHD)的方法,包括向有此需要的对象给予式(I)的化合物。优选地,式(I)中,R3为C2-6烯基,R4为-CN,X1为O,X2为O,Q1为NH,Q2为NH,Q3为NH,Q4为N-R5,R5为C1-6烷基,且L1为C1-6亚烷基。更优选地,所述式(I)的化合物为化合物CS12192。优选地,所述方法可以例如改善移植物抗宿主病(GVHD)患者的存活率或改善移植物抗宿主病(GVHD)患者的体重的增长。优选地,所述移植物抗宿主病为急性移植物抗宿主病(aGVHD)或慢性移植物抗宿主病(cGVHD)。
在一个方面,所述方法还包括向所述对象给予用于预防或治疗移植物抗宿主病(GVHD)的其它活性成分。优选地,所述其它活性成分选自糖皮质激素、钙调神经磷酸酶抑制剂、霉酚酸酯、西罗莫司、喷司他丁、抗CD25单克隆抗体、抗TNFa单克隆抗体、环孢素、甲氨喋呤、沙利度胺或雷帕霉素。优选地,所述糖皮质激素选自泼尼松或甲基泼尼松龙。
本发明所述药物可用于预防或治疗移植物抗宿主病(GVHD),例如,改善移植物抗宿主病(GVHD)患者的存活率或体重。
附图说明
图1是显示化合物CS12192对于GVHD模型中小鼠存活率影响的图;
图2是显示化合物CS12192对于GVHD模型中小鼠体重影响的图。
具体实施方式
除非另外定义,本文所用的所有技术和科学术语具有本领域技术人员通常理解的相同含义。在冲突的情况下,以包括定义在内的本文件为准。下面描述优选的方法和材料,但是与本文所述那些类似或等同的方法和材料可用于实施或测试本发明。本文公开的材料、方法和实例仅是说明性的,而非旨在限制。
本发明提供了用于预防或治疗移植物抗宿主病(GVHD)的药物。在一个方面,本发明提供了用于改善移植物抗宿主病(GVHD)患者的存活率或体重的增长的药物。在一个方面,本发明的药物与本领域已知的药物相比具有更好的效果和/或更少的不良反应。
在一个方面,本发明所述式(I)化合物,特别是CS12192,可以有效治疗GVHD,对于GVHD模型小鼠有着令人满意的治疗获益率,且具有优于一线治疗药物肾上腺皮质激素的药效活性。
在一个方面,本发明涉及式(I)的化合物或其药学上可接受的盐在制备用于预防或治疗移植物抗宿主病(GVHD)的药物中的用途,
其中,
R1为卤素,
R2为卤素,
R3选自C1-6烷基、C2-6烯基或C2-6炔基,
R4选自-CN或卤素,
X1选自O、S、NH或CH2,
X2选自O、S、NH或CH2,
Q1选自NH、CH2、O或S,
Q2选自NH、CH2、O或S,
Q3选自NH、CH2、O或S,
Q4选自N-R5或CH-R5,其中R5选自C1-6烷基、C2-6烯基或C2-6炔基,且
L1选自C1-6亚烷基、C2-6亚烯基或C2-6亚炔基。
在一个方面,所述卤素为例如氟、氯、溴或碘。
在一个方面,所述烷基为例如C1、C2、C3、C4、C5或C6烷基,例如甲基、乙基、丙基、异丙基、丁基、异丁基、叔丁基、戊基、己基。
在一个方面,所述烯基为例如C2、C3、C4、C5或C6烯基,例如乙烯基、丙烯基、丁烯基、戊烯基、己烯基。
在一个方面,所述炔基为例如C2、C3、C4、C5或C6炔基,例如乙炔基、丙炔基、丁炔基、戊炔基、己炔基。
在一个方面,当式(I)中取代基的化学键与环状部分相邻两个环原子之间的化学键相交时,表示该取代基可以与该环状部分任何可能连接的位置连接。
例如,在式(I)中,
R1可以和位置1或2连接,优选和位置1连接;R2可以和位置3、4、5或6连接,优选和位置5连接;R4可以和位置7、8、9、10或11连接,优选和位置9连接。
在一个方面,式(I)中,R3为C2-6烯基,优选为乙烯基,R4为-CN,X1为O,X2为O,Q1为NH,Q2为NH,Q3为NH,Q4为N-R5,R5为C1-6烷基,优选为甲基,且L1为C1-6亚烷基,优选为亚丙基。
在一个方面,所述式(I)的化合物为化合物CS12192:
化合物CS12192的化学名为N-(3-((5-氯-2-((4-氟-3-(N-甲基丙烯酰胺基)苯基)氨基)嘧啶-4-基)氨基)丙基)-4-腈基苯甲酰胺。
中国专利CN105399685B的实施例7公开了化合物CS12192及其制备方法。
在一个方面,所述移植物抗宿主病为急性移植物抗宿主病(aGVHD)或慢性移植物抗宿主病(cGVHD)。
在一个方面,所述药物用于改善移植物抗宿主病(GVHD)患者的存活率。
在一个方面,所述药物用于改善移植物抗宿主病(GVHD)患者的体重的增长。
在一个方面,所述药物还包括用于预防或治疗移植物抗宿主病(GVHD)的其它活性成分。优选地,所述其它活性成分选自糖皮质激素、钙调神经磷酸酶抑制剂、霉酚酸酯、西罗莫司、喷司他丁、抗CD25单克隆抗体、抗TNFa单克隆抗体、环孢素、甲氨喋呤、沙利度胺或雷帕霉素。优选地,所述糖皮质激素选自泼尼松或甲基泼尼松龙。
在一个方面,本发明涉及用于预防或治疗移植物抗宿主病(GVHD)的方法,包括向有此需要的对象给予式(I)的化合物。
在一个方面,所述对象为哺乳动物,例如人。
在一个方面,本发明的药物可以为注射剂、片剂、丸剂、锭剂、软胶囊剂、硬胶囊剂、颗粒剂、散剂、溶液剂、混悬剂、糖浆剂以及任何其他合适的剂型。在一个方面,本发明的药物可口服施用。在一个方面,本发明的药物可肠胃外施用,例如经腹膜内、肌内、动脉内、静脉内、皮下、皮内等途径。
在一个方面,除了活性成份之外,本发明的药物还包含药学上可接受的辅料。作为药学上可接受的辅料,例如可举出润滑剂、粘合剂、填充剂、防腐剂、表面活性剂、着色剂、矫味剂、乳化剂、助悬剂、稀释剂、胶凝剂、崩解剂、pH调节剂、增溶剂等。本领域技术人员知晓,这些辅料可根据合适的剂型适当选择,并视具体需要改变其含量。
实施例
以下实施例显示了式(I)化合物CS12192在GVHD疾病预防和治疗中的应用。
本发明实施例公开了式(I)化合物CS12192在GVHD疾病预防和治疗中的应用。
下面结合具体的实施例,并参照数据进一步详细描述本发明。应理解,这些实施例只是为了举例说明本发明,而非以任何方式限制本发明的范围。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。在以下的实施例中,未详细描述的各种过程和方法是本领域中公知的常规方法。
实施例1.CS12192对小鼠异基因骨髓移植诱导的移植物抗宿主疾病模型的药效学评价
本研究评价测试药CS12192在小鼠异基因骨髓移植诱导的GVHD模型中的药效学作用。在GVHD模型中,用6-8周龄的C57BL/6(H-2b)和BALB/c(H-2d)两种雄性小鼠分别作为供体和受体动物。其中,C57BL/6小鼠为供体小鼠,BALB/c小鼠为受体小鼠。
受体小鼠在移植前一天送到辐照中心接受8.5Gry全身性辐照,辐照结束后,根据小鼠的体重随机分组。在第0天,3-5%异氟烷预麻醉后脱颈椎处死供体小鼠,在无菌环境下摘取脾脏,磨碎后,用无菌滤网过滤。然后用氯化铵缓冲液消化红细胞,再用RPMI 1640培养液洗涤两次淋巴细胞,最后重悬在含10%胎牛血清的RPMI 1640培养液中,制成淋巴细胞悬液。
将受体小鼠分为6组,每组10只。其中第一组同系对照组小鼠尾静脉注射相同数量的BALB/c(H-2d)小鼠细胞;2-5组为同种异系骨髓移植,包括溶媒组、阳性药组和CS12192高、低两个剂量给药组,每只BALB/c(H-2d)受体小鼠尾静脉注射0.5ml的RPMI 1640培养液,其中含同种异系C57BL/6(H-2b)供体鼠的10×106骨髓细胞和6.25×106脾细胞;辐照对照组将不进行任何细胞移植。各组分组及给药情况见表1所示。
表1-给药组及给药方案
CS12192针对小鼠GVHD模型的试验结果显示(图1),小鼠进行同种异系骨髓移植后饲养61天,同种异系骨髓移植对照组的存活率为0,阳性药物泼尼松龙组的存活率为67%(相对溶媒对照p<0.01),CS12192以40和80mg/kg两个剂量,一天两次给药,61天的存活率分别为89%、100%(相对溶媒对照分别p<0.0005和p<0.0001);同时,CS12192两个剂量组小鼠的体重增长也明显优于阳性药物泼尼松龙组,相对溶剂对照组有统计学的增长优势(图2)。上述试验结果表明CS12192可以使GVHD模型小鼠大幅提高存活率,获得综合治疗获益,提示GVHD是CS12192的有效适应症。
虽然本发明某些特征已经在本文中阐释和描述,但本领域技术人员将想到许多修改、替代、变更和等同。因此,应理解的是,所附权利要求书意在涵盖落入本发明真实精神范围之内的所有此类修改、替代、变更和等同。
Claims (9)
2.根据权利要求1所述的用途,其中,R3为C2-6烯基,R4为-CN,X1为O,X2为O,Q1为NH,Q2为NH,Q3为NH,Q4为N-R5,R5为C1-6烷基,且L1为C1-6亚烷基。
4.根据权利要求1所述的用途,其中,所述移植物抗宿主病为急性移植物抗宿主病(aGVHD)或慢性移植物抗宿主病(cGVHD)。
5.根据权利要求1所述的用途,其中,所述药物用于改善移植物抗宿主病(GVHD)患者的存活率。
6.根据权利要求1所述的用途,其中,所述药物用于改善移植物抗宿主病(GVHD)患者的体重的增长。
7.根据权利要求1所述的用途,其中,所述药物还包括用于预防或治疗移植物抗宿主病(GVHD)的其它活性成分。
8.根据权利要求7所述的用途,其中,所述其它活性成分选自糖皮质激素、钙调神经磷酸酶抑制剂、霉酚酸酯、西罗莫司、喷司他丁、抗CD25单克隆抗体、抗TNFa单克隆抗体、环孢素、甲氨喋呤、沙利度胺或雷帕霉素。
9.根据权利要求8所述的用途,其中,所述糖皮质激素选自泼尼松或甲基泼尼松龙。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019110976304 | 2019-11-08 | ||
CN201911097630 | 2019-11-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112773802A true CN112773802A (zh) | 2021-05-11 |
CN112773802B CN112773802B (zh) | 2023-11-21 |
Family
ID=75750410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011235745.8A Active CN112773802B (zh) | 2019-11-08 | 2020-11-06 | 一种化合物用于预防或治疗移植物抗宿主病的用途 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220387430A1 (zh) |
EP (1) | EP4056181A4 (zh) |
JP (1) | JP2023500352A (zh) |
KR (1) | KR20220121793A (zh) |
CN (1) | CN112773802B (zh) |
AU (1) | AU2020381064A1 (zh) |
BR (1) | BR112022008831A2 (zh) |
CA (1) | CA3157631A1 (zh) |
TW (1) | TW202120092A (zh) |
WO (1) | WO2021088975A1 (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102740847A (zh) * | 2009-12-29 | 2012-10-17 | 阿维拉制药公司 | 杂芳基化合物和其用途 |
CN105399685A (zh) * | 2014-09-16 | 2016-03-16 | 深圳微芯生物科技有限责任公司 | 作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105399686B (zh) * | 2014-09-16 | 2018-05-22 | 深圳微芯生物科技有限责任公司 | 嘧啶衍生物、其制备方法及其应用 |
CN105481778B (zh) * | 2014-09-16 | 2019-06-04 | 深圳微芯生物科技股份有限公司 | 嘧啶衍生物、其制备方法及其应用 |
-
2020
- 2020-11-06 BR BR112022008831A patent/BR112022008831A2/pt unknown
- 2020-11-06 JP JP2022526301A patent/JP2023500352A/ja active Pending
- 2020-11-06 CA CA3157631A patent/CA3157631A1/en active Pending
- 2020-11-06 TW TW109138879A patent/TW202120092A/zh unknown
- 2020-11-06 EP EP20883709.6A patent/EP4056181A4/en active Pending
- 2020-11-06 AU AU2020381064A patent/AU2020381064A1/en active Pending
- 2020-11-06 US US17/774,989 patent/US20220387430A1/en active Pending
- 2020-11-06 CN CN202011235745.8A patent/CN112773802B/zh active Active
- 2020-11-06 KR KR1020227018879A patent/KR20220121793A/ko active Search and Examination
- 2020-11-06 WO PCT/CN2020/127064 patent/WO2021088975A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102740847A (zh) * | 2009-12-29 | 2012-10-17 | 阿维拉制药公司 | 杂芳基化合物和其用途 |
CN105399685A (zh) * | 2014-09-16 | 2016-03-16 | 深圳微芯生物科技有限责任公司 | 作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用 |
Non-Patent Citations (2)
Title |
---|
EDWARD G. MCIVER ETAL.: "Synthesis and structure–activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKe kinases", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, vol. 22, pages 7169 - 7133 * |
SONG SHAN ETAL.: "Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor, CS12192, in rat and mouse models of rheumatoid arthritis", 《INTERNATIONAL IMMUNOPHARMACOLOGY》, vol. 77, pages 1 - 9 * |
Also Published As
Publication number | Publication date |
---|---|
CA3157631A1 (en) | 2021-05-14 |
TW202120092A (zh) | 2021-06-01 |
EP4056181A1 (en) | 2022-09-14 |
US20220387430A1 (en) | 2022-12-08 |
EP4056181A4 (en) | 2023-12-20 |
AU2020381064A1 (en) | 2022-06-23 |
KR20220121793A (ko) | 2022-09-01 |
CN112773802B (zh) | 2023-11-21 |
JP2023500352A (ja) | 2023-01-05 |
WO2021088975A1 (zh) | 2021-05-14 |
BR112022008831A2 (pt) | 2022-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2247635T3 (es) | Anticuerpos anti-tnf/receptor de tnf y metotrexato en el tratamiento de enfermedades autoinmunes. | |
US20080008716A1 (en) | Combined Pharmaceutical Composition Comprising an Anti-4-1BB Monoclonal Antibody and Chemotherapeutic Anti-Cancer Agent for Preventing and Treating Cancer Disease | |
HUE029027T2 (en) | Procedures for Multiple Myeloma Treatment Using HuLuc63 and Bortezomib Combination Therapies | |
JP2021028338A (ja) | テノホビルアラフェナミドの結晶形態 | |
TW202017933A (zh) | 用於治療和/或預防與肝炎病毒相關的疾病或病症的雙二氮雜雙環化合物 | |
KR20180041229A (ko) | 줄기 세포 이식을 위한 방법 | |
AU2011246893A1 (en) | Methods and compositions for treating hepatitis with anti-CD3 immune molecule therapy | |
US20080286281A1 (en) | Cd25 binding molecules for the use in the treatment of manifestations of rejection in transplantation | |
US20220387365A1 (en) | Tucaresol derivatives and uses thereof | |
US20190099413A1 (en) | Drug for cancer therapy characterized in that axl inhibitor and immune checkpoint inhibitor are administered in combination | |
CN112773802B (zh) | 一种化合物用于预防或治疗移植物抗宿主病的用途 | |
CN115212209B (zh) | 一种具有免疫佐剂活性和促进免疫疗法的抗肿瘤药物 | |
US20190290673A1 (en) | Compositions and methods for the treatment of hbv infection | |
JP2005511721A (ja) | エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用 | |
US8198293B2 (en) | Oxymatrine compositions and related methods for treating and preventing chronic infectious diseases | |
JP2002530354A5 (zh) | ||
AU2021382954A1 (en) | Pharmaceutical composition, pharmaceutical combined formulation, and combined formulation kit for prevention or treatment of chronic hepatitis b, each comprising, as active ingredient, oral antiviral agent and therapeutic vaccine including lipopeptide and poly(i:c) adjuvant | |
ES2371635T3 (es) | Combinación de un derivado de diamida y agentes inmunosupresores para inhibir el rechazo de transplantes. | |
US20240051962A1 (en) | Solid forms of a nucleoside analogue and uses thereof | |
EP2307018B1 (en) | Oxymatrine compositions and use thereof for treating and preventing chronic infectious diseases | |
WO2020160813A1 (en) | Method of treatment and pharmaceutical dosage form | |
WO2023281434A1 (en) | Use of oligonucleotides for individuals with renal impairment | |
WO2024006461A1 (en) | Solid forms of a nucleoside analogue and uses thereof | |
WO2022152869A1 (en) | Use of oligonucleotides for individuals with hepatic impairment | |
ES2362489T3 (es) | Método para usar eficazmente un medicamento y método concerniente a la prevención de efectos secundarios. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |